BR0108758A - Ecta antiinfectivo - Google Patents

Ecta antiinfectivo

Info

Publication number
BR0108758A
BR0108758A BR0108758-4A BR0108758A BR0108758A BR 0108758 A BR0108758 A BR 0108758A BR 0108758 A BR0108758 A BR 0108758A BR 0108758 A BR0108758 A BR 0108758A
Authority
BR
Brazil
Prior art keywords
provides
compositions
antibiotic resistant
antiinfectant
ect
Prior art date
Application number
BR0108758-4A
Other languages
English (en)
Inventor
H Michael Shepard
Ming Fai Chan
Venkata Ramana Doppalapudi
Brian Edwin Cathers
Mark Stephen Hixon
Thomas J Lobl
Original Assignee
Newbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newbiotics Inc filed Critical Newbiotics Inc
Publication of BR0108758A publication Critical patent/BR0108758A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

"ECTA ANTIINFECTIVO". A presente invenção fornece composições e métodos para objetivar antimetabólitos tóxicos para inibirem o crescimento de infecções microbiais resistentes a antibióticos. Ela fornece um meio de beneficiar-se de um mecanismo de resistência de doença chave para ativar estas drogas localmente, e para superar o fenótipo de resistência dos micróbios. Além disso, a invenção fornece métodos para tratar um sujeito infectado com um microorganismo resistente a antibiótico administrando os compostos ou composições da invenção.
BR0108758-4A 2000-02-28 2001-02-27 Ecta antiinfectivo BR0108758A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18547900P 2000-02-28 2000-02-28
PCT/US2001/006519 WO2001064687A1 (en) 2000-02-28 2001-02-27 Anti-infective ecta?tm¿

Publications (1)

Publication Number Publication Date
BR0108758A true BR0108758A (pt) 2003-03-18

Family

ID=22681148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108758-4A BR0108758A (pt) 2000-02-28 2001-02-27 Ecta antiinfectivo

Country Status (9)

Country Link
EP (1) EP1263762A4 (pt)
JP (1) JP2003525298A (pt)
CN (1) CN1419560A (pt)
AU (1) AU2001241878A1 (pt)
BR (1) BR0108758A (pt)
CA (1) CA2401151A1 (pt)
IL (1) IL151502A0 (pt)
MX (1) MXPA02008368A (pt)
WO (1) WO2001064687A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
WO2002007780A2 (en) * 2000-07-20 2002-01-31 Newbiotics, Inc. Methods for identifying therapeutic targets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348264A (en) * 1980-05-14 1982-09-07 Pfizer Inc. Photocatalyzed process for producing carbapenams and carbapen-2-ems
RO88451A2 (ro) * 1984-06-05 1986-01-30 Intreprinderea De Antibiotice,Ro Derivati ai acidului 7-aminocefalosporanic si procedeu de preparare aacestora

Also Published As

Publication number Publication date
IL151502A0 (en) 2003-04-10
MXPA02008368A (es) 2002-12-13
WO2001064687A1 (en) 2001-09-07
EP1263762A1 (en) 2002-12-11
EP1263762A4 (en) 2003-04-02
CN1419560A (zh) 2003-05-21
JP2003525298A (ja) 2003-08-26
AU2001241878A1 (en) 2001-09-12
CA2401151A1 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
Ippolito et al. Methicillin-resistant Staphylococcus aureus: the superbug
Mahamoud et al. Quinoline derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes isolates
Blanco et al. The development of efflux pump inhibitors to treat Gram-negative infections
ES2556243T3 (es) Agentes terapéuticos que contienen bacteriófagos
Doléans-Jordheim et al. Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains
BRPI0417771A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóides
Dale et al. Therapeutic efficacy of “Nubiotics” against burn wound infection by Pseudomonas aeruginosa
Dusane et al. Targeting intracellular Staphylococcus aureus to lower recurrence of orthopaedic infection
WO2009088549A3 (en) Methods of inhibiting bacterial virulence and compounds relating thereto
IL189017A0 (en) 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-effective agents
TW200630378A (en) Macrolones-amino substituted quinolones
PT1077718E (pt) Melhoramentos da actividade de agentes antibacterianos de oxazolidinona por derivados de arginina
AR014554A1 (es) Compuestos polipeptidos, utiles para el tratamiento de infecciones microbianas, procedimiento para prepararlos, composiciones y medicamentos quelos incluyen y el uso de dichos compuestos y metodo para el tratamiento profilactico y terapeutico de infecciones
EP1037650A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS
BRPI0410940A (pt) benzo[b]tiofenos substituìdos com cicloalquilsulfanila como agentes terapêuticos
DE69428535D1 (de) 36-derivate von rifamycinen und ihre verwendung als antimikrobielles mittel
BR0309757A (pt) 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases
Li et al. Structures, biosynthesis, and bioactivities of prodiginine natural products
BRPI0514892A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR0309878A (pt) Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase
BR0108758A (pt) Ecta antiinfectivo
BRPI0519752A2 (pt) compostos peptÍdicos
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
BR0306901A (pt) Tieno (3,2-b) piridonas como compostos antivirais
ATE413170T1 (de) Medizinische zusammensetzung zur behandlung von infektionen mit arzneimittelresistentem staphylococcus aureus

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]